Vital Signs - Avastin vs. Lucentis: Dollars and Sense

Vital Signs - Avastin vs. Lucentis: Dollars and Sense

 

RELEASE DATE
27-Oct-2008
REGION
North America
Research Code: 9561-00-77-00-00
SKU: HC00550-NA-MR_04022
AvailableYesPDF Download
$1,500.00
In stock
SKU
HC00550-NA-MR_04022
$1,500.00
DownloadLink
ENQUIRE NOW

Description

This issue of Vital Signs, released on October 27, 2008, provides an strategic overview of issues surrounding the usage of Avastin and Lucentis in age-related macular degeneration (AMD) patients. Additionally, a company spotlight is provided for Pipex Pharmaceuticals, a developmental stage specialty pharmaceutical company focused on developing its proprietary drug candidates for the treatment of autoimmune diseases and disorders of the central nervous system. Reimbursement and regulatory news from the FDA is also provided for the week of October 13, 2008.

Table of Contents

This week's issue:

Related Research
This issue of Vital Signs, released on October 27, 2008, provides an strategic overview of issues surrounding the usage of Avastin and Lucentis in age-related macular degeneration (AMD) patients. Additionally, a company spotlight is provided for Pipex Pharmaceuticals, a developmental stage specialty pharmaceutical company focused on developing its proprietary drug candidates for the treatment of autoimmune diseases and disorders of the central nervous system. Reimbursement and regulatory news from the FDA is also provided for the week of October 13, 2008.
More Information
No Index Yes
Podcast No
Industries Healthcare
WIP Number 9561-00-77-00-00
Is Prebook No